Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease

References

• Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:2489-99
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs. long-acting beta-agonists monotherapy for stable COPD. Chest 2009;136:1029-38
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD006829
   PubMed Web of Science ®Google Scholar
• Cazzola M, Santus P, Di Marco F, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003;97:453-7
   PubMed Web of Science ®Google Scholar
• Hanania NA, Ambrosino N, Calverley P, et al. Treatments for COPD. Respir Med 2005;99(Suppl B):S28-40
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Gaga M, et al. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets 2013;14:192-224
   PubMed Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controller trials. Thorax 2013;68:48-56
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. CG101 chronic obstructive pulmonary disease (update): full guideline 23 June 2010. Available from: www.nice.org [Last accessed 30 April 2014]
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2014. Available from: www.goldcopd.org/ [Last accessed 30 April 2014]
   Google Scholar
• Miravitlles M, Soler-Catalunã JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol 2012;48:247-57
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta2-agonists and corticosteroids in stable COPD. Chest 2004;126:220-37
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163:29-43
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
   PubMed Web of Science ®Google Scholar
• Simoni-Wastila L, Wei YJ, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother 2012;10:201-10
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-501
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Pharmaceutical approval update. P.T 2013;38:389-403
   PubMedGoogle Scholar
• Revinty Ellipta. Summary of opinion (initial authorisation). Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002745/WC500163485.pdf [Last accessed 30 April 2014]
   Google Scholar
• Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007;8:54
   PubMed Web of Science ®Google Scholar
• McCormack PL, Scott LJ. Fluticasone furoate. Drugs 2007;67:1905-15
   PubMed Web of Science ®Google Scholar
• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011;670:244-51
   PubMed Web of Science ®Google Scholar
• Nasreen N, Gonzalves L, Peruvemba S, Mohammed KA. Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells. Int Immunopharmacol 2014;19:153-60
   PubMed Web of Science ®Google Scholar
• Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet 2013;52:885-96
   PubMed Web of Science ®Google Scholar
• Allen A, Bal J, Cheesbrough A, et al. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Br J Clin Pharmacol 2014;77:808-20
   PubMed Web of Science ®Google Scholar
• Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013;52:37-42
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 µg) improves lung function in COPD: a randomised trial. Resp Med 2013;107:550-9
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 2010;53:4522-30
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013;344:218-30
   PubMed Web of Science ®Google Scholar
• Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting β2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos 2013;41:89-100
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013;26:256-64
   PubMed Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142:119-27
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013;107:560-9
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012;67:35-41
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012;2:e000370
   PubMed Web of Science ®Google Scholar
• Boscia JA, Pudi KK, Zvarich MT, et al. Effect of once-daily fluticasone furoate/vilanterol on 24-h pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther 2012;34:1655-66
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23
   PubMed Web of Science ®Google Scholar
• Agustí A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014;43:763-72
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Crim CC, Feldman G, et al. Once-daily (OD) fluticasone furoate/vilanterol (FF/VI: 100/25mcg) compared with twice-daily (BD) fluticasone propionate/salmeterol (FSC: 250/50mcg) in patients with COPD [abstract]. Am J Respir Crit Care Med 2013;187:A2432
   Google Scholar
• FDA Advisory Committee Briefing Document. BREO™ ELLIPTA™ (Fluticasone Furoate/Vilanterol Inhalation Powder) for treatment of chronic obstructive pulmonary disease. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM347931.pdf [Last accessed 12 May 2014]
   Google Scholar
• Kempsford R, Allen A, Kelly K, et al. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects. Br J Clin Pharmacol 2014;77:466-79
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Li H, Hinds D, et al. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis 2014;9:457-68
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev 2014;75:18-31
   PubMed Web of Science ®Google Scholar
• Hamilton M, Prime D, Bogalo Huescar M, et al. In–vitro delivery performance of umeclidinium and umeclidinium/vilanterol from a dry powder inhaler using the Electronic Lung breathing simulator to replicate inhalation profiles from patients with varying COPD severity. Abstract Am J Respir Crit Care Med 2013;187:A4281
   Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22:92-100
   PubMedGoogle Scholar
• Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8
   PubMedGoogle Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106:989-97
   PubMed Web of Science ®Google Scholar
• Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6:493-501
   PubMed Web of Science ®Google Scholar
• Gordon J. GlaxoSmithKline - Upgrading to Neutral, upside from upcoming catalysts balances out earnings risk. Available from: https://markets.jpmorgan.com/research/email/eevpt8pp/GPS-1190044-0.pdf [Last accessed 19 May 2014]
   Google Scholar
• Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs 2012;72:301-8
   PubMed Web of Science ®Google Scholar
• Cecere LM, Slatore CG, Uman JE, et al. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease. COPD 2012;9:251-8
   PubMedGoogle Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-43
   PubMed Web of Science ®Google Scholar
• Price D, Lee AJ, Sims EJ, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013;22:161-8
   PubMedGoogle Scholar
• Bollmeier SG, Prosser TR. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2014;48:250-7
   PubMed Web of Science ®Google Scholar
• Beeh KM. All I want for Christmas is two: the advent of novel fixed-combination inhalers for COPD and outlook for 2014. Adv Ther 2013;30:1033-7
   PubMed Web of Science ®Google Scholar
• Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther 2014;18(4):381-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012;48:785-94
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41:1017-22
   PubMed Web of Science ®Google Scholar